Back to Peptide Index

Selank

NeuroEvidence Level: researchNot FDA-approved; ongoing research and clinical studies support its therapeutic potential.
Peptide #09

Selank is a synthetic peptide derived from tuftsin, a naturally occurring immunomodulatory peptide, widely studied for its anxiolytic (anti-anxiety), nootropic (cognitive-enhancing), and neuroprotective properties. It modulates neurotransmitter systems, particularly affecting serotonin, dopamine, and norepinephrine levels, improving stress response, reducing anxiety symptoms, and enhancing emotional stability without causing sedation or dependence. Selank also enhances cognitive performance, improves memory, attention, learning, and overall cognitive function, attributed to its ability to increase levels of brain-derived neurotrophic factor (BDNF) and support neuroplasticity. It exhibits immunomodulatory effects, contributing to improved neurological health by reducing inflammation and oxidative stress within the brain.

Alternative Names:

Heptapeptide analog of tuftsin

Overview

Selank is a synthetic peptide derived from tuftsin, studied for its anxiolytic, nootropic, and neuroprotective properties. It modulates neurotransmitter systems, improves stress response, reduces anxiety symptoms, and enhances emotional stability without causing sedation or dependence.

How It Works

Selank modulates neurotransmitter systems, particularly affecting serotonin, dopamine, and norepinephrine levels. It increases levels of brain-derived neurotrophic factor (BDNF) and supports neuroplasticity, influencing immune function and exerting neuroprotective effects by modulating inflammatory responses and enhancing neuronal survival.

Clinical Effects

Reduces anxiety symptoms, stress responses, and emotional distress; enhances cognitive performance, memory, attention, learning, and overall cognitive function; promotes emotional stability and mental resilience.

Therapeutic Applications

Anxiety disorders, cognitive impairment, depression, chronic stress, neurological and immune-related disorders.

Research Studies

Clinical Trials

Human trials have demonstrated promising initial results for anxiety management, cognitive enhancement, and stress reduction.

Preclinical Studies

Preclinical studies support its use as a nootropic agent, with potential applications in cognitive impairment, academic performance, and cognitive resilience enhancement.

Frequently Asked Questions

Is Selank legally available? Yes, Selank is legally available for research purposes from specialized suppliers but is not approved for general therapeutic use. Have human trials been conducted with Selank? Yes, human trials have demonstrated promising initial results for anxiety management, cognitive enhancement, and stress reduction. However, further comprehensive studies are necessary. What are potential side effects of Selank? Reported side effects are minimal and typically mild, including transient headache, dizziness, or mild fatigue. Comprehensive long-term safety studies are ongoing. How is Selank typically administered? Selank is typically administered via intranasal sprays or subcutaneous injections in research settings, with dosage protocols tailored to specific experimental objectives. Can Selank be combined with other cognitive enhancers or anxiolytics? Selank is often explored in combination with other nootropics or anxiolytics in research studies. However, controlled studies are essential to establish safe and effective combination protocols. Does Selank permanently enhance cognitive functions? Selank enhances cognitive functions and reduces anxiety symptoms during administration. Sustained benefits generally require ongoing or periodic treatments.

Quick Information

Safety Information

Safety Profile

Comprehensive long-term safety studies are ongoing.

Contraindications

Side Effects: Minimal and typically mild, including transient headache, dizziness, or mild fatigue. Safety Profile: Comprehensive long-term safety studies are ongoing.

Side Effects

Minimal and typically mild, including transient headache, dizziness, or mild fatigue.

Research References

Kozlovskaya, M.M., et al. (2003). The anxiolytic activity of the peptide Selank. Bulletin of Experimental Biology and Medicine. Ashmarin, I.P., et al. (2005). Selank is a new synthetic peptide anxiolytic. Bulletin of Experimental Biology and Medicine. Semenova, T.P., et al. (2008). Effect of Selank on cognitive processes in experimental animals. Neuroscience and Behavioral Physiology.

Additional Resources